Royalty Pharma Declares Third Quarter 2022 Dividend
July 15 2022 - 8:15AM
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has
approved the payment of a dividend for the third quarter of 2022 of
$0.19 per Class A ordinary share.
The dividend will be paid on September 15, 2022, to shareholders
of record at the close of business on August 19, 2022.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
non-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on around 35 commercial products, including AbbVie and
Johnson & Johnson’s Imbruvica, Johnson & Johnson’s Tremfya,
Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy,
Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and
Trikafta, and 10 development-stage therapies. For more information,
visit www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6772ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Jul 2023 to Jul 2024